330792-70-6

Basic information

• Product Name: 5-aMino-3-(4-phenoxyphenyl)-1H-pyrazole-4-carbonitrile
• Synonyms: 5-aMino-3-(4-phenoxyphenyl)-1H-pyrazole-4-carbonitrile;3-AMino-4-cyano-5-(4-phenoxyphenyl)pyrazole;1H-Pyrazole-4-carbonitrile, 3-aMino-5-(4-phenoxyphenyl)-;3-amino-5-(4-phenoxyphenyl)-1H-Pyrazole-4-carbonitrile
• CAS NO: 330792-70-6
• Molecular Formula: C₁₆H₁₂N₄O
• Molecular Weight: 276.29268
• Mol File: 330792-70-6.mol
• Article Data: 26

Chemical Properties

• Boiling Point: 585.3±50.0 °C(Predicted)
• Appearance: /
• Density: 1.37±0.1 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 10.83±0.50(Predicted)
• CAS DataBase Reference: 5-aMino-3-(4-phenoxyphenyl)-1H-pyrazole-4-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 5-aMino-3-(4-phenoxyphenyl)-1H-pyrazole-4-carbonitrile(330792-70-6)
• EPA Substance Registry System: 5-aMino-3-(4-phenoxyphenyl)-1H-pyrazole-4-carbonitrile(330792-70-6)

Safety Data

• Hazardous Substances Data: 330792-70-6(Hazardous Substances Data)

Usage

Description

5-aMino-3-(4-phenoxyphenyl)-1H-pyrazole-4-carbonitrile is an organic compound characterized by its unique molecular structure, which features a pyrazole ring fused with a phenyl group. 5-aMino-3-(4-phenoxyphenyl)-1H-pyrazole-4-carbonitrile is known for its potential applications in various fields due to its chemical properties and reactivity.

Uses

Used in Pharmaceutical Industry:
5-aMino-3-(4-phenoxyphenyl)-1H-pyrazole-4-carbonitrile is used as a reactant for the preparation of ring-fused pyrazole derivatives, which are known to be inhibitors of lymphocyte-specific kinase (Lck). These derivatives have potential applications in the development of drugs targeting autoimmune diseases and other conditions related to the immune system.
Used in Chemical Synthesis:
In the field of chemical synthesis, 5-aMino-3-(4-phenoxyphenyl)-1H-pyrazole-4-carbonitrile serves as a valuable building block for the creation of more complex molecules with diverse applications. Its reactivity and structural features make it a useful component in the synthesis of various organic compounds, including pharmaceuticals, agrochemicals, and other specialty chemicals.

Upstream product

• 330792-69-3 2-[(4-phenoxy-phenyl)-methoxy-methylene]-malononitrile 
• 1623-95-6 4-phenoxybenzoyl chloride 
• 109-77-3 malononitrile 
• 21218-94-0 methyl 4-phenoxybenzoate 
• 2215-77-2 4-Phenoxybenzoic acid 
• 330792-68-2 2-[hydroxy-(4-phenoxy-phenyl)-methylene]-malononitrile 
• 619-44-3 methyl 4-iodobenzoate 
• 108-95-2 phenol 
• 1055710-57-0 2-[amino(4-phenoxyphenyl)methylene]malononitrile 

Downstream Products

• 928309-79-9 C₂₄H₁₉BrN₄O 
• 1207957-96-7 C₂₅H₂₁BrN₄O 
• 928309-83-5 C₂₅H₂₁BrN₄O₂ 
• 928309-86-8 C₂₅H₂₁BrN₄O₂ 
• 1558038-40-6 C₂₇H₂₉N₅O₃ 
• 1558038-41-7 C₂₂H₂₃N₅O₂ 
• 1558037-08-3 C₃₀H₃₄N₆O₄ 
• 1558036-72-8 C₂₆H₂₅N₅O₃ 
• 1558038-55-3 C₂₈H₃₃N₅O₄ 
• 1558037-28-7 C₂₆H₂₇N₅O₃ 
• 1558038-54-2 C₂₈H₃₁N₅O₃ 
• 1612774-47-6 tert-butyl 3-(5-amino-4-cyano-3-(4-phenoxyphenyl)-1H-pyrazol-1-yl)-piperidine-1-carboxylate 
• 1612774-50-1 (R)-tert-butyl 3-(5-amino-4-cyano-3-(4-phenoxyphenyl)-1H-pyrazol-1-yl)piperidine-1-carboxylate 
• 1612774-51-2 (R)-tert-butyl 3-(5-amino-4-carbamoyl-3-(4-phenoxyphenyl)-1H-pyrazol-1-yl)piperidine-1-carboxylate 

Relevant articles and documents

Regioselective Synthesis of Highly Functionalized Pyrazoles from N-Tosylhydrazones

A regioselective synthesis of highly functionalized pyrazoles from N-tosylhydrazones was developed. The reaction was general for a wide range of substrates and demonstrated excellent tolerance to a variety of substituents, and the method has been successfully applied to the formal synthesis of ibrutinib.

TREATMENT OF INDOLENT OR AGGRESSIVE B-CELL LYMPHOMAS USING A COMBINATION COMPRISING BTK INHIBITORS

Disclosed herein is a method for the prevention, delay of progression or treatment of indolent or aggressive B-cell lymphomas in an individual in need thereof, comprising administering a Btk inhibitor (in particularly (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo-[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof) in combination with an anti-PD-1 antibody. The potent and selective BTK inhibitor in combination with the anti-PD-1 antibody have a manageable toxicity profile in patients with indolent and aggressive lymphomas.

Methods of Using BTK Inhibitors to Treat Dermatoses

In certain embodiments, the invention includes therapeutic methods of using a BTK inhibitor to treat dermatoses, such as psoriasis, atopic dermatitis, contact dermatitis, scleroderma, and cutaneous lupus erythematosus. In other embodiments, the methods of the invention further comprise the step of administering a therapeutically effective dose of an anti-inflammatory agent.